• News release
  • /
  • In brief
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
CFDA Granted Approval of Phase I-III ...
Clinical Trials of Sirotinib (XZP - 5491) by CFDA...
CFDA Granted Approval of Phase II/III...
Phase II/ III Clinical Trials of Imigliptin Hydr...
XuanZhu Pharma Co., Ltd. is an international research and development (R&D) enterprise of innovative drugs. Founded in 2002 with the registered capital of 50 million yuan,XuanZhu Pharma is focused on R&D of new chemical entities. It is a wholly-owned subsidiary and innovative drug research institute of Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharma). Sihuan Pharma, listed in Hong Kong (stock code: 00460.HK) on October 28, 2010, has developed into a multi-functional pharmaceutical group company, covering ...
資質榮譽
  • 發展歷程
  • /
  • 研發平臺
CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287,a Category 1.1 Innovative Drug
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride,a category 1.1 antidiabetic drug
The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects;Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development;FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug;The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA;CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug.
CFDA Granted Approval of Phase I to III Clinical Trials for XZP-3287,a Category 1.1 Innovative Drug
CFDA Granted Approval of Phase II/III Clinical Trials for Imigliptin Hydrochloride,a category 1.1 antidiabetic drug
The injectable antibiotic Benapenem, National Category 1.1 new drug, is tested on human for the first time. It is well tolerated in subjects;Covance and XuanZhu Pharma announce partnership for preclinical and clinical portfolio development;FPI is achieved in the US for Pirotinib, National Category 1.1 anti-cancer new drug;The IND of national Category 1.1 anti-oncology new drug Sirotinib is approved by CFDA;CFDA granted IND applications to Pirotinib Hydrochloride, a category 1.1 anti-oncology drug.

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

青海快3十大规律 天天捕鸟官方最新版本 海王捕鱼礼包兑换码 幸运农场网技巧 天津麻将技巧 一波中特期期准有吗 皇家真人棋牌 六六大顺顺是什么肖 申城棋牌官方网 四川麻将单机版 捕鱼单机无需网络版